CALC Projected Dividend Yield
CalciMedica Inc ( NASDAQ : CALC )CalciMedica is a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve. Co.'s product candidate, GB-102, is an intravitreal injection of a microparticle depot formulation of sunitinib, a potent inhibitor of neovascular growth and permeability, which are causes of retinal disease. Co.'s second product candidate, GB-401, is an intravitreally administered, proprietary implant formulation containing a prodrug of a beta-adrenergic receptor inhibitor developed to provide a controlled release of the active drug to maintain reduced intraocular pressure, for six months or longer after a single injection. 20 YEAR PERFORMANCE RESULTS |
CALC Dividend History Detail CALC Dividend News CALC Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |